Curaleaf Holdings, Inc. (CURLF) Q2 2025 Earnings Call Transcript

Curaleaf Holdings reported Q2 2025 revenue of $315 million, a modest 1.5% sequential increase, with adjusted EBITDA of $66 million, representing a 21% margin. While domestic sales remained largely flat due to persistent price compression, the international segment was a significant growth driver, increasing 17% sequentially and 62% year-over-year, bolstered by strong performance in Germany and the UK, and strategic moves like securing a license for Turkey and achieving EU medical device registration. CEO Boris Jordan highlighted the company's focus on scale amid industry rationalization and stated a readiness to potentially spin out the International or Hemp businesses if meaningful federal cannabis reform, particularly 280E relief, does not materialize by year-end, to unlock perceived undervalued assets.

Analysis

Curaleaf's Q2 2025 results present a clear dichotomy between its stabilizing domestic operations and its rapidly accelerating international segment. The company reported revenue of $315 million, reflecting a modest 1.5% sequential increase, and adjusted EBITDA of $66 million, or a 21% margin. This performance was anchored by the international business, which grew 17% sequentially to $41 million, driven by robust demand in Germany and the UK. In stark contrast, domestic sales remained flat quarter-over-quarter due to persistent price compression, which offset growth in key states like Florida and Ohio. Management attributed this pressure not to regulated competition but to the largely untaxed and unregulated hemp and illicit markets. Adjusted gross margin contracted 130 basis points sequentially to 49%, a direct result of increased promotional activity around the 4/20 holiday.

Strategically, the company is fortifying its global leadership through significant international milestones, including acquiring 100% ownership of its international arm, securing a first-mover license in Turkey's 87-million-person market, and achieving EU medical device certification for a proprietary inhalation product. These developments underscore a pivot towards high-growth, pharma-like medical markets, which management views as substantially undervalued within the current corporate structure. The CEO issued a significant strategic signal, stating that if meaningful U.S. federal reform, particularly 280E tax relief, fails to materialize by year-end, the company is prepared to spin out its international and hemp businesses to unlock value. Financially, the company ended the quarter with $102 million in cash after generating $9 million in operating cash flow and is on track to complete a crucial debt refinancing by the end of the year. The guidance for Q3 revenue to be flat to up low-single digits suggests near-term headwinds persist.

Key Decisions for Investors

• Investors should assess Curaleaf as a bifurcated company, weighing the stagnant, price-pressured U.S. business against the high-growth international segment, which is now the primary driver of value.
• The potential spin-off of the international and hemp businesses represents a significant catalyst; monitor U.S. federal cannabis reform progress, as a lack of 280E relief by year-end could trigger this value-unlocking event.
• Given the flat to low-single-digit revenue guidance for Q3 and ongoing U.S. price compression, near-term expectations for domestic profitability and growth should be tempered.
• Focus on international execution as a key performance indicator, specifically tracking revenue momentum in Germany, progress in the new Turkish market, and adoption of the EU-certified medical device.